These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17680622)

  • 1. Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CHF patients.
    Konstantino Y; Kusniec J; Reshef T; David-Zadeh O; Mazur A; Strasberg B; Battler A; Haim M
    Clin Cardiol; 2007 Aug; 30(8):408-13. PubMed ID: 17680622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.
    Medina A; Moss AJ; McNitt S; Zareba W; Wang PJ; Goldenberg I
    Heart Rhythm; 2016 Apr; 13(4):852-9. PubMed ID: 26724489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm.
    Streitner F; Kuschyk J; Veltmann C; Ratay D; Schoene N; Streitner I; Brueckmann M; Schumacher B; Borggrefe M; Wolpert C
    Cytokine; 2009 Sep; 47(3):166-72. PubMed ID: 19604708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
    Manios EG; Kallergis EM; Kanoupakis EM; Mavrakis HE; Kambouraki DC; Arfanakis DA; Vardas PE
    Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
    Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
    J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Brain natriuretic peptide (BNP) level predicts long term ventricular arrhythmias in patients with moderate to severe left ventricular dysfunction].
    Galante O; Zahger D; Wagshal A; Katz A; Amit G
    Harefuah; 2012 Jan; 151(1):20-3, 63, 62. PubMed ID: 22670496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants.
    De Sutter J; Tavernier R; De Bacquer D; De Buyzere M; Van de Veire NR; Jordaens L; Matthys K; Bernard D; Langlois M; De Backer G
    Int J Cardiol; 2006 Sep; 112(1):72-9. PubMed ID: 16316699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%.
    Grimm W; Hoffmann J Jü; Müller HH; Maisch B
    J Am Coll Cardiol; 2002 Mar; 39(5):780-7. PubMed ID: 11869841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipients--a pilot study.
    Streitner F; Kuschyk J; Veltmann C; Brueckmann M; Streitner I; Brade J; Neumaier M; Bertsch T; Schumacher B; Borggrefe M; Wolpert C
    Cytokine; 2007 Oct; 40(1):30-4. PubMed ID: 17851087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator.
    Gardiwal A; Yu H; Oswald H; Luesebrink U; Ludwig A; Pichlmaier AM; Drexler H; Klein G
    Europace; 2008 Mar; 10(3):358-63. PubMed ID: 18308756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Wang W; Lian Z; Rowin EJ; Maron BJ; Maron MS; Link MS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28314849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction.
    Matsumoto M; Tsujino T; Lee-Kawabata M; Naito Y; Sakoda T; Ohyanagi M; Masuyama T
    Cytokine; 2010 Mar; 49(3):264-8. PubMed ID: 20005739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy.
    Rosenthal TM; Stahls PF; Abi Samra FM; Bernard ML; Khatib S; Polin GM; Xue JQ; Morin DP
    Heart Rhythm; 2015 Aug; 12(8):1789-97. PubMed ID: 25998895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of nonsustained and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
    Zhou X; Gunderson BD; Olson WH;
    J Cardiovasc Electrophysiol; 2004 Jan; 15(1):14-20. PubMed ID: 15028067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.